DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
TRLV logo

Trulieve Cannabis Corp. Stock Price

NYSE:TRLV Community·US$2.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 20 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

TRLV Share Price Performance

US$11.31
4.57 (67.80%)
​
US$18.18
Fair Value
US$11.31
4.57 (67.80%)
37.8% undervalued intrinsic discount
US$18.18
Fair Value
Price US$11.31
AnalystConsensusTarget US$18.18
AnalystLowTarget US$15.00
AnalystHighTarget US$21.00
Thu, 13 Aug 26
Fair ValueUS$18.18
Share Pricen/a

TRLV Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$18.18 37.8% undervalued intrinsic discount

Federal Rescheduling And Medical Expansion Will Support A Stronger Long Term Cannabis Operator

1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$15 24.6% undervalued intrinsic discount

Rescheduling Uncertainty And Texas Execution Risks Will Pressure Results Yet Support Long Term Upside

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$21 46.1% undervalued intrinsic discount

Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
TRLV logo
Trulieve Cannabis
37.8% undervalued intrinsic discount

Federal Rescheduling And Medical Expansion Will Support A Stronger Long Term Cannabis Operator

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 13 Aug
Read Narrative
TRLV logo
Trulieve Cannabis
46.1% undervalued intrinsic discount

Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 11 Aug
Read Narrative
TRLV logo
Trulieve Cannabis
24.6% undervalued intrinsic discount

Rescheduling Uncertainty And Texas Execution Risks Will Pressure Results Yet Support Long Term Upside

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 30 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
TRLV logo

TRLV: Federal Rescheduling And NYSE Listing Will Support Future Upside Potential

Fair Value: US$18.18 37.8% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
TRLV logo

Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power

Fair Value: US$21 46.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
TRLV logo

TRLV: Federal Rescheduling And Georgia Expansion Will Drive Future Upside

Fair Value: US$15 24.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Very undervalued with adequate balance sheet.

1 Risk
3 Rewards
View Full Analysis

Trulieve Cannabis Corp. Key Details

US$1.1b

Revenue

US$461.6m

Cost of Revenue

US$677.4m

Gross Profit

US$1.1b

Other Expenses

-US$467.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-2.43
59.47%
-41.07%
37.9%
View Full Analysis

About TRLV

Founded
1940
Employees
5000
CEO
Kimberly Rivers
WebsiteView website
www.trulieve.com

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, oral, topical, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company also offers medical cannabis dispensary in North Miami Beach, Florida. Trulieve Cannabis Corp. was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Tallahassee, Florida.

Recent TRLV News & Updates

Seeking Alpha • Sep 11

Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards

Summary Trulieve Cannabis Corp. is reinitiated as a Buy, driven by regulatory catalysts and attractive valuation after a recent 81% rally. Rescheduling of medicinal cannabis to Schedule III eliminates punitive tax burdens, boosts cash flows, and enables greater R&D and financing flexibility for TRLV. TRLV is well-positioned for growth through Florida consolidation, expansion into Texas and Alabama, and potential upside from a $583M tax liability reversal. Trading at a forward EV/EBITDA of 6.92 versus a sector median of 12.5, TRLV offers compelling value and strong balance sheet support amid competitive risks. Read the full article on Seeking Alpha
User avatar
Narrative Update • Aug 13

TRLV: Federal Rescheduling And NYSE Listing Will Support Future Upside Potential

Analysts recently trimmed their fair value estimate for Trulieve Cannabis from about $19.42 to roughly $18.18, citing updated assumptions around discount rates, revenue trends, profit margins, and future P/E multiples. These changes align with a new $15 analyst price target and expectations for the company to benefit from U.S. medical cannabis growth following federal rescheduling.

Recent updates

No updates

Trulieve Cannabis Corp. Competitors

ICLR logo

ICON

Symbol: NasdaqGS:ICLR
Market cap: US$13.1b
BMRN logo

BioMarin Pharmaceutical

Symbol: NasdaqGS:BMRN
Market cap: US$12.7b
MDGL logo

Madrigal Pharmaceuticals

Symbol: NasdaqGS:MDGL
Market cap: US$12.3b
CORT logo

Corcept Therapeutics

Symbol: NasdaqCM:CORT
Market cap: US$12.2b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide